Skip to main content

Table 1 Baseline characteristics from the training and validation datasets

From: Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study

 

Training

Validation

P-value

Age, years (range)

60.4 (36–88)

60.4 (31–84)

0.331

Sex, n (%)

  

0.045

 Male

164 (75.2%)

144 (66.1%)

 

 Female

54 (24.8%)

74 (33.9%)

 

Smoking history, n (%)

  

0.101

 Never

112 (51.4%)

130 (59.6%)

 

 Former/current

106 (48.6%)

88 (40.4%)

 

Metastatic sites, n (%)

  

0.233

 1–2

208 (95.4%)

201 (92.2%)

 

 3

10 (4.6%)

17 (7.8%

 

Classification, n (%)

  

0.690

 Synchronous

137 (62.8%)

142 (65.1%)

 

 Metachronous

81 (37.2%)

76 (34.9%)

 

Pathology, n (%)

  

0.616

 Adenocarcinoma

164 (75.2%)

171 (78.4%)

 

 Non-adenocarcinoma

47 (21.6%)

45 (20.6%)

 

 Unknown

7 (3.2%)

2 (1.0%)

 

EGFR status, n (%)

  

0.911

 Negative

110 (50.5%)

107 (49.1%)

 

 Positive

77 (35.3%)

82 (37.6%)

 

 Unknown

31 (14.2%)

29 (13.3%)

 

T stage, n (%)

  

0.851

 T0–2

149 (68.3%)

155 (71.1%)

 

 T3–4

67 (30.7%)

61 (27.9%)

 

N stage, n (%)

  

0.282

 N0

49 (22.5%)

63 (28.9%)

 

 N+

169 (77.5%)

155 (71.1%)

 

LCT

  

0.968

 Surgery

17 (7.8%)

15 (6.9%)

 

 Radiotherapy

79 (36.2%)

80 (36.7%)

 

 Both

4 (1.8%)

3 (1.4%)

 

 Neither

118 (54.2%)

120 (55.0%)

 

Total

218

218

 
  1. EGFR epidermal growth factor receptor; LCT local consolidative therapy